Common Cardiac Effects of Lacosamide
Lacosamide, an antiepileptic drug used for partial-onset seizures, commonly causes cardiac conduction abnormalities due to its selective slowing of voltage-gated sodium channels in cardiac tissue. The most frequent effects include PR interval prolongation, seen in up to 43% of patients in clinical trials, and atrioventricular (AV) block (first-, second-, or third-degree), occurring in 0.4-1% of cases.[1][2]
How Lacosamide Affects the Heart
It primarily prolongs the PR interval by delaying AV nodal conduction without significantly altering QRS duration or QT interval at therapeutic doses. Dose-dependent effects emerge above 400 mg/day, with higher risks in patients with underlying heart disease. ECG monitoring is recommended during initiation or dose escalation.[1][3]
Frequency of Specific Effects
- PR prolongation (>200 ms): 9-43% across studies, often asymptomatic.
- First-degree AV block: 1-4%.
- Second- or third-degree AV block: <1%, but requires immediate discontinuation.
- Atrial fibrillation/flutter: 1-2%, more common in elderly patients.
- Other: Bradycardia (0.5-1%), palpitations (1-3%).[1][2][4]
Risks in Patients with Heart Conditions
Patients with sick sinus syndrome, second- or third-degree AV block, or severe conduction delays face heightened risk of bradycardia or syncope; lacosamide is contraindicated here. Use caution with beta-blockers or calcium channel blockers, as they amplify PR prolongation.[1][3]
What Happens If Cardiac Effects Occur
Mild PR prolongation often resolves with dose reduction. Severe cases (e.g., high-degree AV block) demand stopping the drug and pacemaker evaluation if symptomatic. Routine ECGs at baseline, 6 weeks, and periodically thereafter help detect issues early.[1][2]
Comparison to Other Antiepileptics
Unlike carbamazepine or lamotrigine, which rarely prolong PR intervals, lacosamide's cardiac profile resembles that of sodium channel blockers like lidocaine. It shows less QT prolongation than ezogabine but more conduction slowing than levetiracetam.[3][4]
Sources
[1]: Lacosamide Prescribing Information (Vimpat), UCB, 2023
[2]: Epilepsia Clinical Trial Data on Lacosamide Cardiac Safety
[3]: FDA Label Warnings for Cardiac Effects
[4]: Review in Current Neurology Reports, 2021